Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Stomach Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2-low Breast Cancer 1HER2 1Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1

Interventions

pyrotinib 2pertuzumab 2Trastuzumab 2disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-positive Metastatic Breast Cancer × disitamab vedotin × Clear all
NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡